Opsumit (macitentan) has been made available by Actelion for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH.
Due to its Boxed Warning regarding potential fetal harm, female patients can receive the drug only through the Opsumit Risk Evaluation and Mitigation Strategy (REMS) Program.
Opsumit is currently available as 10mg strength tablets in 15 count blister packs and 30 count bottles.
For more information call (866) 228-3546 or visit Opsumit.com.